We have located links that may give you full text access.
The role of pleural fluid Thiol/Disulfide Homeostasis in the differentiation between transudative and exudative pleural effusions.
International Journal of Clinical Practice 2021 January 26
OBJECTIVE: In the present study, we aimed to differentiate between transudative and exudative pleural effusions using thiol sulfide homeostasis, an oxidative stress marker.
DESIGN: This was a prospective study.
SETTING: Emergency Department of Ankara City Hospital, between 1 January 2020 and 15 May 2020 SUBJECTS: Patients who were diagnosed with pleural effusion and underwent thoracentesis to make a differentiation between transudative and exudative pleural effusions. The patients were divided into two groups as those who have transudative pleural effusion and those who have exudative pleural effusion. These two groups were assessed with respect to demographic features and oxidative stress parameters.
MAIN OUTCOME MEASURES: Oxidative stress parameters(The native thiol (NT), total thiol (TT), and disulfide (D) levels and their ratios to one another were calculated (index 1: D/NT, index 2:D/TT, index 3: NT/TT).
RESULTS: This study enrolled a total of 50 patients with pleural effusion. 20 patients (40%) were male, and 30 patients (60%) were female. In the transudative pleural effusion group, 14 patients (56%) had decompensated heart failure, 9 patients (36%) had hepatic cirrhosis, and 2 patients (8%) had hypoalbuminemia. In the exudative pleural effusion group, 17 patients (68%) had malignancy, 7 patients (28%) had parapneumonic effusion, and 1 patient (4%) had pulmonary embolism. TT (p<0.001) and NT (p=0.001) values were significantly lower in the transudative pleural effusion group compared to the exudative pleural effusion group whereas there was no significant difference between the two groups with respect to D (p=0. ,489), index 1 (p=0.07), index 2 (p=0.064), and index 3 (p=0.063) values.
CONCLUSION: We believe that a differentiation can be made between transudative and exudative pleural fluids by using thiol sulfide homeostasis, an oxidative stress marker.
DESIGN: This was a prospective study.
SETTING: Emergency Department of Ankara City Hospital, between 1 January 2020 and 15 May 2020 SUBJECTS: Patients who were diagnosed with pleural effusion and underwent thoracentesis to make a differentiation between transudative and exudative pleural effusions. The patients were divided into two groups as those who have transudative pleural effusion and those who have exudative pleural effusion. These two groups were assessed with respect to demographic features and oxidative stress parameters.
MAIN OUTCOME MEASURES: Oxidative stress parameters(The native thiol (NT), total thiol (TT), and disulfide (D) levels and their ratios to one another were calculated (index 1: D/NT, index 2:D/TT, index 3: NT/TT).
RESULTS: This study enrolled a total of 50 patients with pleural effusion. 20 patients (40%) were male, and 30 patients (60%) were female. In the transudative pleural effusion group, 14 patients (56%) had decompensated heart failure, 9 patients (36%) had hepatic cirrhosis, and 2 patients (8%) had hypoalbuminemia. In the exudative pleural effusion group, 17 patients (68%) had malignancy, 7 patients (28%) had parapneumonic effusion, and 1 patient (4%) had pulmonary embolism. TT (p<0.001) and NT (p=0.001) values were significantly lower in the transudative pleural effusion group compared to the exudative pleural effusion group whereas there was no significant difference between the two groups with respect to D (p=0. ,489), index 1 (p=0.07), index 2 (p=0.064), and index 3 (p=0.063) values.
CONCLUSION: We believe that a differentiation can be made between transudative and exudative pleural fluids by using thiol sulfide homeostasis, an oxidative stress marker.
Full text links
Related Resources
Trending Papers
Guillain-Barré syndrome: History, pathogenesis, treatment, and future directions.European Journal of Neurology 2024 May 17
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction.Pharmacological Research : the Official Journal of the Italian Pharmacological Society 2024 May 12
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app